Press Release
15.10.21

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers

Zurich-Schlieren, Switzerland, October 15th, 2021. TOPADUR Pharma AG, a clinical-stage biopharmaceutical start-up company developing first-in-class drugs for aging diseases, today is pleased to announce that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to TOP-N53, the company’s lead product, for the treatment of digital ulcers in patients with systemic sclerosis (SSc).

“This ODD by EMA marks an important milestone in the clinical development of TOP-N53 and supports our conviction that innovative treatments for chronic wounds are urgently needed” said Reto Naef, Chairman of the Board of Directors and CEO at TOPADUR Pharma AG. “TOP-N53 potency, tolerability and efficacy were demonstrated in First-in-Human study. We believe that this novel drug candidate has the potential to transform the standard of care of digital ulcers in SSc patients and to provide a valuable treatment option for this disabling condition.”

Download DocumentDokument herunterladen
15.10.21
Press Release

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.

Read more
27.5.21
News

Innosuisse innovation project starting May 2021

TOPADUR in collaboration with the University Hospital of Zurich and the University of Zurich was awarded CHF 859k by Innosuisse.

Read more
20.5.20
News

Scientific Publication in the Journal of Investigative Dermatology

A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Promotes Wound Healing in Normal and Diabetic Mice.

Read more